2012
Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial
Anstead M, Heltshe SL, Khan U, Barbieri JT, Langkamp M, Döring G, Dharia S, Gibson RL, Treggiari MM, Lymp J, Rosenfeld M, Ramsey B. Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial. Journal Of Cystic Fibrosis 2012, 12: 147-153. PMID: 22944725, PMCID: PMC3696392, DOI: 10.1016/j.jcf.2012.08.001.Peer-Reviewed Original ResearchConceptsPulmonary exacerbationsCF patientsP. aeruginosa eradicationP. aeruginosa isolationCystic fibrosis patientsEarly P. aeruginosaBaseline seropositivityEPIC trialPositive serologyAntibiotic therapyChild TrialTreatment failurePrognostic valuePseudomonas infectionWeek 10Fibrosis patientsSerologyCulture resultsPatientsClinicians' effortsExacerbationSeropositivityP. aeruginosaRiskTrials
2011
Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis
Mayer‐Hamblett N, Kronmal RA, Gibson RL, Rosenfeld M, Retsch‐Bogart G, Treggiari MM, Burns JL, Khan U, Ramsey BW, Investigators F. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonology 2011, 47: 125-134. PMID: 21830317, PMCID: PMC3214247, DOI: 10.1002/ppul.21525.Peer-Reviewed Original ResearchConceptsExacerbation riskInitial eradicationCystic fibrosisPseudomonas aeruginosa acquisitionInitial antibiotic treatmentPositive respiratory culturesPA recurrenceProportional hazards modelSymptom-based definitionEPIC trialPulmonary exacerbationsAntibiotic therapyTreatment failureClinical benefitPA infectionRespiratory culturesSubsequent exacerbationAntibiotic treatmentEarly eradicationHigh riskNegative culturesExacerbationHazards modelSignificant predictorsTrials